2025 Annual Meeting | C21 - Neurological Complications of Checkpoint Inhibitors

��ɫ��

2025 Annual Meeting | C21 - Neurological Complications of Checkpoint Inhibitors

Date Saturday 04/05/25

Time 12:00 PM - 02:00 PM PDT Add To Calendar

Location San Diego Convention Center | 25B

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Jorg Dietrich, MD, PhD, FAAN

Topic(s) Neuro-oncology

Learning Objectives Participants should gain an understanding of potential neurotoxic side effects of novel immunotherapies, including immune checkpoint inhibitors and CAR-T cells; learn to recognize clinical and imaging patterns of neurotoxicity after immunotherapy; and be able to discuss current management options and identify strategies designed to improve patient outcome.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Interpersonal and Communication Skills, Professionalism, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice, Quality Improvement

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Case-based, Didactic

Program Materials Program Evaluations

Event Timeline
12:00 PM - 12:40 PM PDT	Speaker	Neurological Complications of Immune Checkpoint Inhibitors Leonie Muller-Jensen, MD
12:40 PM - 01:20 PM PDT	Speaker	At the Crossroads of Checkpoint Inhibitor-Related Neurotoxicity and Paraneoplastic Syndromes Antonio Farina
01:20 PM - 02:00 PM PDT	Speaker	CAR-T cell Associated Neurological Complications Jorg Dietrich, MD, PhD, FAAN

Faculty Disclosures
Jorg Dietrich, MD, PhD, FAAN	Dr. Dietrich has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Dietrich has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Dietrich has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ono Therapeutics. Dr. Dietrich has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Johnson & Johnson. Dr. Dietrich has received publishing royalties from a publication relating to health care.
Antonio Farina	Mr. Farina has nothing to disclose.
Leonie Muller-Jensen, MD	Dr. Muller-Jensen has nothing to disclose.

��ɫ����

��ɫ����

��ɫ��

��ɫ��